City of Hope’s investigational COVID-19 vaccine generates robust immune response

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


City of Hope and Charles R. Drew University of Medicine and Science, the only Historically Black Graduate Institution west of the Mississippi River and one of only four Historically Black Medical Schools, announced the launch of a new partnership to educate a more diverse workforce in specialized medicine through internships, curriculum, training, mentorships, joint research projects, and more.